Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Nutcracker Therapeutics logo — Nutcracker Therapeutics is developing mRNA therapeutics and...

Nutcracker Therapeutics

Nutcracker Therapeutics is developing mRNA therapeutics and a novel GMP manufacturing platform.

Founded 2018 United States Emeryville, United States 55 employees Series C Total: $241.00M

General Information

Company Name Nutcracker Therapeutics
Founded Year 2018
Location United States Emeryville, United States
Employees 55
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Nutcracker Therapeutics. To contact Nutcracker Therapeutics, visit nutcrackerx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nutcracker Therapeutics compare?

A PDF of Nutcracker Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nutcracker Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nutcracker Therapeutics

Nutcracker Therapeutics is at the forefront of innovation in the biotech industry with its focus on mRNA therapeutics and a novel GMP manufacturing platform. Founded in 2018, this biotechnology CRDMO firm integrates advanced engineering and high-precision biosynthesis to harness the potential of RNA technology.

Their platform innovatively streamlines the design, delivery, and manufacturing of RNA molecules, promising a reduction in costs and cycle times without compromising quality. This scalable RNA platform sets them apart in a competitive landscape, demonstrating a distinct technological edge.

In the investment sphere, Nutcracker Therapeutics secured a substantial $167.00M Series C investment on 01 March 2022, with Arch Venture Partners as a key investor. This robust financial backing suggests strong market confidence in their vision and potential for growth within the burgeoning field of personalized RNA-based therapeutics.

Business keywords: mRNA therapeutics, GMP manufacturing, CRDMO, advanced engineering, biosynthesis, RNA technology, personalized therapeutics, technology platform, RNA molecule design, RNA delivery, RNA manufacturing, cost reduction, cycle time reduction, high-quality production, scalable RNA platform

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $167.00M 1
Arch Venture Partners
Arch Venture Partners
01 Mar 2022
Series B $60.00M 2
Arch Venture Partners Bluebird Ventures
Arch Venture Partners, Bluebird Ventures
01 Sep 2020
Early VC $10.00M -
01 Mar 2019
Early VC $4.00M -
01 May 2018

Nutcracker Therapeutics Alternatives & Competitors

View All Alternatives
Nutcracker Therapeutics vs
Wizme
Wizme United Kingdom

Smart meets fast. The intelligent meetings and groups management platform built for high performance...

Pre-Seed
12 employees
Analytics, Enterprise Software
Nutcracker Therapeutics vs
Pantherna Therapeutics GmbH
Pantherna Therapeutics GmbH Germany

Developing novel mRNA-based therapeutics

Seed
11 employees
Biotechnology, Health Care
Nutcracker Therapeutics vs
NextRetreat
NextRetreat United Kingdom

Award-winning organizer of team offsites, meetups and company retreats around the globe.

Seed
9 employees
B2B, Health and Wellness
View all alternatives

FAQ About Nutcracker Therapeutics

Nutcracker Therapeutics is developing mRNA therapeutics and a novel GMP manufacturing platform.
Nutcracker Therapeutics was founded in 2018.
Nutcracker Therapeutics is headquartered in Emeryville, United States.
Nutcracker Therapeutics has approximately 55 employees.
Nutcracker Therapeutics has completed 4 funding rounds, raising a total of $241.00M. The latest funding stage is Series C.
Top alternatives and competitors to Nutcracker Therapeutics include Wizme, Pantherna Therapeutics GmbH, NextRetreat, RequirementONE, Cisterna Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nutcracker Therapeutics and Wizme are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nutcracker Therapeutics, https://bouncewatch.com/company/nutcracker-therapeutics, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout